CIDP
MCID: CHR283
MIFTS: 40

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

About this section
Sources:
31ICD10 via Orphanet, 35LifeMap Discovery®, 48NIH Rare Diseases, 49NINDS, 54Orphanet, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 35 48 49 54
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 48 54
 
Cidp 48 54
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 68

Characteristics:

Orphanet epidemiological data:

54
chronic inflammatory demyelinating polyneuropathy:
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy

Classifications:



External Ids:

Orphanet54 ORPHA2932
UMLS via Orphanet69 C0393819
ICD10 via Orphanet31 G61.8

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

About this section
NIH Rare Diseases:48 Chronic inflammatory demyelinating polyneuropathy (cidp) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. symptoms often include tingling or numbness (first in the toes and fingers); weakness of the arms and legs; loss of deep tendon reflexes; fatigue; and abnormal sensations. cidp is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. cidp is closely related to guillain-barre syndrome (gbs) and is considered the "chronic counterpart" of gbs. treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physiotherapy, and/or intravenous immunoglobulin (ivig) therapy. left untreated, 30% of people with cidp will progress to wheelchair dependence. last updated: 2/27/2017

MalaCards based summary: Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to chronic myelomonocytic leukemia and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is AIF1 (Allograft Inflammatory Factor 1), and among its related pathways are Spinal Cord Injury and NCAM1 interactions. The drug immunoglobulins, intravenous has been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and skin.

NINDS:49 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia:71 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Diseases in the Demyelinating Polyneuropathy family:

chronic inflammatory demyelinating polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 106)
idRelated DiseaseScoreTop Affiliating Genes
1chronic myelomonocytic leukemia28.4AIF1, CNTN2, GDNF, HLA-DRB1, HP, TTR
2chronic inflammatory demyelinating polyradiculoneuropathy12.5
3chronic inflammatory demyelinating polyneuritis11.2
4polyneuropathy11.2
5demyelinating polyneuropathy11.2
6polyradiculoneuropathy11.1
7neuropathy, inflammatory demyelinating10.8
8neuropathy10.5
9hepatitis10.2
10charcot-marie-tooth disease10.1
11myasthenia gravis10.1
12tooth disease10.1
13poems syndrome10.1
14melanoma10.1
15hepatitis b10.1
16multifocal motor neuropathy10.1
17meningeal melanoma10.0AIF1, TTR
18hematocele of tunica vaginalis testis10.0HP, TTR
19glomerulonephritis10.0
20lymphoma10.0
21respiratory failure10.0
22spastic entropion10.0HP, TTR
23systemic lupus erythematosus9.9
24charcot-marie-tooth disease, type 1a9.9
25arthritis9.9
26crohn's disease9.9
27diabetic neuropathy9.9
28focal segmental glomerulosclerosis9.9
29scoliosis9.9
30diabetic polyneuropathy9.9
31guillain-barre syndrome9.9
32mononeuritis multiplex9.9
33hepatitis c9.9
34tuberculosis9.9
35myopathy9.9
36neuronitis9.9
37lupus erythematosus9.9
38psoriasis9.9
39intracranial hypertension9.9
40amyloid neuropathy9.9
41endotheliitis9.9
42penis agenesis9.9HLA-DRB1, TTR
43endogenous depression9.9HLA-DRB1, HP
44focal epithelial hyperplasia9.9HP, TTR
45periarthritis9.9HLA-DRB1, HP
46choreatic disease9.8HLA-DRB1, HP
47rheumatoid arthritis9.8
48myocardial infarction9.8
49hepatocellular carcinoma9.8
50hepatitis c virus9.8

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to chronic inflammatory demyelinating polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1AntibodiesPhase 4, Phase 3, Phase 2, Phase 16394
2Rho(D) Immune GlobulinPhase 4, Phase 3, Phase 2326
3Immunoglobulins, IntravenousPhase 4, Phase 3, Phase 2333
4gamma-GlobulinsPhase 4, Phase 3, Phase 2326
5ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16394
6
Prednisoneapproved, vet_approvedPhase 3139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
7
Mycophenolic acidapprovedPhase 395224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
8
Mycophenolate mofetilapproved, investigationalPhase 3952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
9
BenzocaineapprovedPhase 320161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
10
Glycineapproved, nutraceutical, vet_approvedPhase 323256-40-6750
Synonyms:
(1-13c)glycinato
(15N)Glycine
15527_RIEDEL
15527_SIAL
15743-44-9 (mono-potassium salt)
17829-66-2 (cobalt salt)
18875-39-3
2,2-dialkylglycines
2-Aminoacetate
2-Aminoacetic acid
2311-65-1
25718-94-9
29728-27-6 (monoammonium salt)
32817-15-5 (copper salt)
33226_RIEDEL
33226_SIAL
33242-26-1 (calcium salt)
35947-07-0 (calcium salt (2:1))
410225_SIAL
50046_FLUKA
50046_SIGMA
513-29-1 (sulfate (3:1))
52955-63-2
56-40-6
57678-19-0
6000-43-7 (hydrochloride)
6000-44-8 (mono-hydrochloride salt)
63183-41-5 (hydrochloride hydrogen carbonate)
71295-98-2 (phosphate (1:1))
7490-95-1 (hydrochloride (2:1)
7490-95-1 (hydrochloride (2:1))
7575-55-5
848646-45-7
87867-94-5
AB-131/40217813
AB1002628
AC1L19XW
AC1Q28JW
AC1Q53O0
AI3-04085
AKOS000119626
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
AR-1A0345
AR-1A0532
Acide aminoacetique
Acide aminoacetique [INN-French]
Acido aminoacetico
Acido aminoacetico [INN-Spanish]
Acidum aminoaceticum
Acidum aminoaceticum [INN-Latin]
Aciport
Amino-Acetate
Amino-Acetic acid
Aminoacetate
Aminoacetic acid
Aminoazijnzuur
Aminoessigsaeure
Aminoethanoate
Aminoethanoic acid
Amitone
B72BA06C-60E9-4A83-A24A-A2D7F465BB65
BPBio1_001222
Biomol-NT_000195
C00037
CCRIS 5915
CHEBI:15428
CHEBI:15705
CHEBI:16228
CHEMBL773
CID750
CPD-8569
Corilin
D00011
DB00145
EINECS 200-272-2
 
FEMA No. 3287
FT-0083159
G
G0099
G0317
G5417_SIGMA
G5523_SIGMA
G7126_SIGMA
G7403_SIGMA
G8790_SIGMA
G8898_SIGMA
GLY (IUPAC abbrev)
GLYCINE 1.5% IN PLASTIC CONTAINER
GLYCINE, ACS
Glicina
Glicina [INN-Spanish]
Glicoamin
Gly
Glycin
Glycine
Glycine (JP15/USP)
Glycine [INN]
Glycine iron sulphate (1:1)
Glycine, homopolymer (VAN)
Glycine, labeled with carbon-14
Glycine, non-medical
Glycine-UL-14C hydrochloride
Glycinum
Glycinum [INN-Latin]
Glycocoll
Glycolixir
Glycosthene
Glykokoll
Glyzin
Gyn-Hydralin
Gyn-hydralin
H-Gly-OH
H2N-CH2-COOH
HSDB 495
Hampshire glycine
Hgly
InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5
KST-1A2919
KST-1A8102
L-Glycine
L-alpha-amino acids
L001246
LS-218
Leimzucker
MolPort-000-871-607
NCGC00024503-01
NCGC00024503-02
NChemBio.2007.13-comp1
NSC 25936
NSC25936
P8791_SIGMA
Padil
Polyglycine II
S04-0135
Sucre de gelatine
Tocris-0219
UNII-TE7660XO1C
W328707_ALDRICH
WLN: Z1VQ
aminoacetic acid
an alpha amino acid ester
bmse000089
gly
glycine
nchem.554-comp2
nchembio.121-comp9
nchembio.145-comp33
nchembio.198-comp12
nchembio.265-comp9
nchembio.266-comp30
polyglycine
11tannic acidapproved, NutraceuticalPhase 32016
12Potassium Channel BlockersPhase 3180
13Anti-Inflammatory AgentsPhase 310729
14Immunosuppressive AgentsPhase 3, Phase 213086
15Immunoglobulin GPhase 3275
163,4-diaminopyridinePhase 320
17HormonesPhase 3, Phase 214415
18Hormone AntagonistsPhase 3, Phase 213180
19Fingolimod HydrochloridePhase 388
20Antineoplastic Agents, HormonalPhase 35592
21glucocorticoidsPhase 35103
22Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 213168
23Pharmaceutical SolutionsPhase 3, Phase 28192
24Antibiotics, AntitubercularPhase 37180
25Anti-Bacterial AgentsPhase 311226
26
Interferon beta-1aapproved, investigationalPhase 2200145258-61-36438354
Synonyms:
145258-61-3
Avonex
Avonex (TN)
Belerofon
D04554
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
Interferon beta-1a
Interferon beta-1a (USAN)
Interferon beta-1a (genetical recombination)
Interferon beta-1a (genetical recombination) (JAN)
27
Folic Acidapproved, nutraceutical, vet_approvedPhase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
28VitaminsPhase 25282
29Interferon-betaPhase 2284
30Adjuvants, ImmunologicPhase 22554
31Anti-Infective AgentsPhase 222062
32Antiviral AgentsPhase 29967
33Vitamin B ComplexPhase 24337
34Trace ElementsPhase 26001
35interferonsPhase 22175
36MicronutrientsPhase 26001
37Protective AgentsPhase 27443
38Thioctic AcidPhase 2118
39AntioxidantsPhase 23050
40Alpha-lipoic AcidNutraceuticalPhase 2118
41Vitamin B9NutraceuticalPhase 24392
42FolateNutraceuticalPhase 24392
43Antibodies, Anti-Idiotypic18

Interventional clinical trials:

(show all 42)
idNameStatusNCT IDPhase
1IVIg for Demyelination in Diabetes MellitusRecruitingNCT02372149Phase 4
2Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)WithdrawnNCT01757574Phase 4
3Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.CompletedNCT01824251Phase 3
4Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT01184846Phase 3
5Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)CompletedNCT01545076Phase 3
6Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00220740Phase 3
7Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.CompletedNCT01625182Phase 3
8Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIgCompletedNCT01349270Phase 3
9Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00004772Phase 3
10Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating NeuropathyCompletedNCT00004286Phase 3
11Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating PolyneuropathyCompletedNCT00004939Phase 3
12Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPRecruitingNCT02955355Phase 3
13Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDPRecruitingNCT02549170Phase 3
14Efficacy and Safety Study of I10E in Treatment of Patients With CIDPRecruitingNCT02293460Phase 3
15Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302RecruitingNCT02317562Phase 3
16Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Active, not recruitingNCT02027701Phase 3
17Interest of Mycophenolate for CIDP WeaningActive, not recruitingNCT02494505Phase 3
18Panzyga in CIDP Administered at Different Infusion RatesNot yet recruitingNCT03166527Phase 3
19Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) NeuropathyNot yet recruitingNCT02638207Phase 3
20Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPTerminatedNCT01225276Phase 2, Phase 3
21Lipoic Acid to Treat Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00962429Phase 2
22Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00001287Phase 2
23Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT00099489Phase 2
24Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT01017159Phase 2
25Stem Cell Transplantation for Stiff Person Syndrome (SPS)RecruitingNCT02282514Phase 1, Phase 2
26SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot StudyRecruitingNCT02967679Phase 1, Phase 2
27Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruitingNCT00278629Phase 2
28High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating PolyneuropathyWithdrawnNCT01236456Phase 2
29Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating NeuropathyWithdrawnNCT02574962Phase 2
30Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating PolyneuropathyUnknown statusNCT01379833
31Effect of Resistance and Aerobic Exercise in CIDP or MMNCompletedNCT02121678
32MRI in Diagnosing and Monitoring CIDPCompletedNCT02017769
33Immunoglobulin Dosage and Administration Form in CIDP and MMNCompletedNCT02111590
34Study of CIDP Patients During IVIG TreatmentCompletedNCT00305266
35Magnetic Resonance Diagnostics of Diabetic Peripheral NeuropathyCompletedNCT01847937
36Subcutaneous Immunoglobulin for CIDPRecruitingNCT02465359
37IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength MeasurementsRecruitingNCT02414490
38sCD163 & CD19 as Candidate Biomarkers in CIDP and MMNRecruitingNCT02271724
39Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT02629796
40Transcriptome Analysis of the Peripheral Blood in CIDPRecruitingNCT02404298
41Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous ImmunoglobulinNot yet recruitingNCT02892890
42Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and NeuroNot yet recruitingNCT03008733

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS68/NDF-RT46:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells, PMID: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

36
T cells, Bone, Skin, Spinal cord, Endothelial, B cells, Thyroid

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50)    (show all 521)
idTitleAuthorsYear
1
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. (28000311)
2017
2
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. (28073817)
2017
3
Postural tremor and chronic inflammatory demyelinating polyneuropathy. (27421831)
2016
4
Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. (26843559)
2016
5
Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. (27401495)
2016
6
Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. (26900579)
2016
7
Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. (27793469)
2016
8
Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. (27930572)
2016
9
Poster 487 Chronic Inflammatory Demyelinating Polyneuropathy or Something Else?: A Case Report. (27673228)
2016
10
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. (27389526)
2016
11
Evaluation of Patients with Refractory Chronic Inflammatory Demyelinating Polyneuropathy. (27463215)
2016
12
Intrathecal Dexmedetomidine for Anaesthetic Management of a Patient with Chronic Inflammatory Demyelinating Polyneuropathy. (27790558)
2016
13
Anti-ganglioside antibodies in Guillain-BarrAc syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients. (27464289)
2016
14
Chronic inflammatory demyelinating polyneuropathy variant (Lewis- Sumner syndrome) in HIV. (27727849)
2016
15
Poster 373-A Immunoglobulin Treatment of Miller Fisher Variant of Acute Demyelinating Inflammatory Polyneuropathy with Underlying Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. (27673265)
2016
16
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. (26924156)
2016
17
Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies. (27986399)
2016
18
Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP). (27677703)
2016
19
Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity. (27211536)
2016
20
Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation. (26919852)
2016
21
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. (27455854)
2016
22
Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy. (26809024)
2016
23
Chronic inflammatory demyelinating polyneuropathy associated with Rickettsia conorii: First case report. (27871450)
2016
24
Poster 353 Acute Onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) with CNS Involvement Initially Diagnosed as Guillain-Barre Syndrome (GBS): A Case Report. (27673107)
2016
25
The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. (27546708)
2016
26
A case of intravenous immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy of pure motor form responsive to mycophenolate mofetil therapy. (27680225)
2016
27
Incidence and Natural History of Idiopathic Chronic Inflammatory Demyelinating Polyneuropathy: A Population-Based Study in Iceland. (27211228)
2016
28
Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin. (27114080)
2016
29
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-I+ Therapy With Infliximab for Crohn's Disease. (27144200)
2016
30
Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). (27208993)
2016
31
Electrophysiological and neuromuscular stability of persons with chronic inflammatory demyelinating polyneuropathy (CIDP). (27997686)
2016
32
Chronic inflammatory demyelinating polyneuropathy associated with manic symptoms. (27571998)
2016
33
Disease activity in chronic inflammatory demyelinating polyneuropathy. (27653889)
2016
34
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. (27086491)
2016
35
Poster 11 A Rare Case of Chronic Inflammatory Demyelinating Polyneuropathy in the Setting of SLE: A Case Report. (27672778)
2016
36
Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. (25814494)
2015
37
Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. (25976871)
2015
38
Conducting processes in simulated chronic inflammatory demyelinating polyneuropathy at 20A^C-42A^C. (25597276)
2015
39
Dramatic Improvement of Chronic Inflammatory Demyelinating Polyneuropathy Through Tenofovir Treatment in a Patient Infected with Hepatitis B Virus. (25850895)
2015
40
Chronic inflammatory demyelinating polyneuropathy associated with neurosyphilis. (25470500)
2015
41
Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions. (26425012)
2015
42
Acute-Onset chronic inflammatory demyelinating polyneuropathy. An electrodiagnostic study. (25809534)
2015
43
Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus. (25819084)
2015
44
Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. (26439954)
2015
45
Electrotonic potentials in simulated chronic inflammatory demyelinating polyneuropathy at 20A^C-42A^C. (25916252)
2015
46
Treatment of chronic inflammatory demyelinating polyneuropathy. (26008811)
2015
47
Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. (26268846)
2015
48
A case of chronic inflammatory demyelinating polyneuropathy with reversible alternating diaphragmatic paralysis: case study. (26490681)
2015
49
Recurrent Isolated Sixth Nerve Palsy in Relapsing-Remitting Chronic Inflammatory Demyelinating Polyneuropathy. (26301375)
2015
50
Chronic inflammatory demyelinating polyneuropathy with membranous nephropathy. (25977098)
2015

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Expression for genes affiliated with Chronic Inflammatory Demyelinating Polyneuropathy

About this section
Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for genes affiliated with Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.5AIF1, GDNF
29.3CNTN2, GDNF
39.0CNTN2, HLA-DRB1

GO Terms for genes affiliated with Chronic Inflammatory Demyelinating Polyneuropathy

About this section

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuron projection developmentGO:00311759.3CNTN2, GDNF

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet